Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center

Published:2018-08 Issue:4 Volume:28 Page:341-347
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Afzal Muhammad Z.,Shirai Keisuke

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference30 articles.

1. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

2. B7S1, a novel B7 family member that negatively regulates T cell activation;Prasad;Immunity,2003

3. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma;Phan;Proc Natl Acad Sci USA,2003

4. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma;Fischkoff;Proc Am Soc Clin Oncol,2005

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases;Lung Cancer;2024-07

2. Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation;Journal for ImmunoTherapy of Cancer;2024-05

3. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations;European Journal of Cancer;2024-05

4. Immunotherapy for hepatocellular carcinoma: molecular pathogenesis and clinical research progress;Oncology and Translational Medicine;2023-12-22

5. Management of metastatic bone disease of melanoma;Melanoma Research;2023-11-07